MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide

被引:156
作者
Chen, XY
Park, R
Hou, YP
Khankaldyyan, V
Gonzales-Gomez, I
Tohme, M
Bading, JR
Laug, WE
Conti, PS
机构
[1] Univ So Calif, Keck Sch Med, Dept Radiol, PET Imaging Sci Ctr, Los Angeles, CA 90033 USA
[2] Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA 90027 USA
关键词
angiogenesis; integrin; RGD; PEGylation; MicroPET;
D O I
10.1007/s00259-003-1452-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
We have previously labeled cyclic RGD peptide c(RGDyK) with fluorine-18 through conjugation labeling via a prosthetic 4-[F-18]fluorobenzoyl moiety and applied this [F-18]FB-RGD radiotracer for alpha(v)-integrin expression imaging in different preclinical tumor models with good tumor-to-background contrast. However, the unfavorable hepatobiliary excretion and rapid tumor washout rate of this tracer limit its potential clinical applications. The aims of this study were to modify the [F-18]FB-RGD tracer by inserting a heterobifunctional poly(ethylene glycol) (PEG, M.W. = 3,400) between the F-18 radiolabel and the RGD moiety and to test this [F-18]FB-PEG-RGD tracer for brain tumor targeting and in vivo kinetics. [F-18]FB-PEG-RGD was prepared by coupling the RGD-PEG conjugate with N-succinimidyl 4-[F-18]fluorobenzoate ([F-18]SFB) under slightly basic conditions (pH=8.5). The radiochemical yield was about 20-30% based on the active ester [F-18]SFB, and specific activity was over 100 GBq/mumol. This tracer had fast blood clearance, rapid and high tumor uptake in the subcutaneous U87MG glioblastoma model (5.2 +/- 0.5%ID/g at 30 min p.i.). Moderately rapid tumor washout was observed, with the activity accumulation decreased to 2.2 +/- 0.4%ID/g at 4 h p.i. MicroPET and autoradiography imaging showed a very high tumor-to-background ratio and limited activity accumulation in the liver, kidneys and intestinal tracts. U87MG tumor implanted into the mouse forebrain was well visualized with [F-18]FB-PEG-RGD. Although uptake in the orthotopic tumor was significantly lower (P<0.01) than in the subcutaneous tumor, the maximum tumor-to-brain ratio still reached 5.0 +/- 0.6 due to low normal brain background. The results of H&E staining postmortem agreed with the anatomical information obtained from non-invasive microPET imaging. In conclusion, PEGylation suitably modifies the physiological behavior of the RGD peptide. [F-18]FB-PEG-RGD gave improved tumor retention and in vivo kinetics compared with [F-18]FB-RGD.
引用
收藏
页码:1081 / 1089
页数:9
相关论文
共 37 条
[1]   Molecular epidemiology of glioblastoma [J].
Aldape, KD ;
Okcu, MF ;
Bondy, ML ;
Wrensch, M .
CANCER JOURNAL, 2003, 9 (02) :99-106
[2]  
Armstrong Terri S, 2002, J Neurosci Nurs, V34, P326
[3]   Polyethylene glycol-conjugated pharmaceutical proteins [J].
Bailon, P ;
Berthold, W .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1998, 1 (08) :352-356
[4]  
BRENNER B, 1996, BRENNER REACTORS KID
[5]   Current and future strategies for the treatment of malignant brain tumors [J].
Castro, MG ;
Cowen, R ;
Williamson, IK ;
David, A ;
Jimenez-Dalmaroni, MJ ;
Yuan, X ;
Bigliari, A ;
Williams, JC ;
Hu, J ;
Lowenstein, PR .
PHARMACOLOGY & THERAPEUTICS, 2003, 98 (01) :71-108
[6]   18F-labeled RGD peptide:: initial evaluation for imaging brain tumor angiogenesis [J].
Chen, XY ;
Park, R ;
Shahinian, AH ;
Tohme, M ;
Khankaldyyan, V ;
Bozorgzadeh, MH ;
Bading, JR ;
Moats, R ;
Laug, WE ;
Conti, PS .
NUCLEAR MEDICINE AND BIOLOGY, 2004, 31 (02) :179-189
[7]   Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation [J].
Chen, XY ;
Park, R ;
Shahinian, AH ;
Bading, JR ;
Conti, PS .
NUCLEAR MEDICINE AND BIOLOGY, 2004, 31 (01) :11-19
[8]   SYNTHESIS OF 2'-FLUORO-5-[C-11]-METHYL-1-BETA-D-ARABINOFURANOSYLURACIL ([C-11]-FMAU) - A POTENTIAL NUCLEOSIDE ANALOG FOR IN-VIVO STUDY OF CELLULAR PROLIFERATION WITH PET [J].
CONTI, PS ;
ALAUDDIN, MM ;
FISSEKIS, JR ;
SCHMALL, B ;
WATANABE, KA .
NUCLEAR MEDICINE AND BIOLOGY, 1995, 22 (06) :783-789
[9]   N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists [J].
Dechantsreiter, MA ;
Planker, E ;
Mathä, B ;
Lohof, E ;
Hölzemann, G ;
Jonczyk, A ;
Goodman, SL ;
Kessler, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (16) :3033-3040
[10]  
DELGADO C, 1992, CRIT REV THER DRUG, V9, P249